Ocular Hypertension - Pipeline Insight, 2021
SKU ID :DEL-17687658 | Published Date: 15-Mar-2021 | No. of pages: 60Description
TOC
Introduction
Executive Summary
Ocular Hypertension: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Ocular Hypertension – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Ocular Hypertension companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ocular Hypertension Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
NCX 470: Nicox
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Sepetaprost DE-126: Santen Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Ocular Hypertension Key Companies
Ocular Hypertension Key Products
Ocular Hypertension- Unmet Needs
Ocular Hypertension- Market Drivers and Barriers
Ocular Hypertension- Future Perspectives and Conclusion
Ocular Hypertension Analyst Views
Ocular Hypertension Key Companies
Appendix
Tables & Figures
Table 1 Total Products for Ocular Hypertension
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Companies
• Nicox
• Santen Pharmaceutical
• AbbVie
• MediPrint Ophthalmics
• Whitecap Biosciences
• Ocular Therapeutix
• Sylentis
• Chong Kun Dang Pharmaceutical
• Aerpio Pharmaceuticals
- PRICE
-
$1500$4500